Denali Therapeutics Inc.

Katrina W Lexa

Zachary Kevin Sweeney

Anthony A Estrada

Javier De Vicente Fidalgo

Jianwen A Feng

Maksim Osipov

Robert A Craig, Ii

Brian M Fox

Travis Remarchuk

Christopher R H Hale

Gunasekaran Kannan

Ankita Srivastava

Rachel Prorok

Gerald Maxwell Cherf

Ray L Y Low

Robert A Ii Craig

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

Compounds, compositions and methods

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

Modulators of eukaryotic initiation factor 2B, compositions and methods

Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.

Progranulin variants

Growing community of inventors

San Francisco, CA, United States of America

Katrina W Lexa